0001179929-26-000023
SEC filingMolina Healthcare's net income plunged 95% to $14 million due to a $93 million impairment charge and higher medical costs, while revenue fell 4% on membership declines.
Molina Healthcare reported a sharp decline in profitability for Q1 2026. Total revenue decreased 3.2% to $10.80 billion from $11.15 billion in Q1 2025, driven by a 4% drop in premium revenue to $10.17 billion. The premium revenue decline reflected lower Medicaid membership due to general market contraction and the expiration of the Virginia contract, partially offset by rate updates. Marketplace premium revenue fell 28% as the company pursued a pricing strategy to restore margins. Medicare premium grew 3% on product mix changes and the ConnectiCare acquisition.
Medical margin (premium revenue minus medical care costs) fell 21.5% to $902 million, with the consolidated medical care ratio (MCR) rising to 91.1% from 89.2%. All segments experienced higher MCRs: Medicaid (+170 bps to 92.0%), Medicare (+150 bps to 89.8%), and Marketplace (+230 bps to 84.0%). The increase was primarily due to elevated utilization and changes in estimate for prior year risk adjustment.
Operating income collapsed to $83 million from $433 million, impacted by the weaker medical margin and a $93 million impairment charge related to the planned exit of the Medicare Advantage-Part D (MAPD) product. Net income plunged 95% to $14 million ($0.27 per diluted share) from $298 million ($5.45). The effective tax rate surged to 52.8% from 23.7% due to nondeductible expenses and unfavorable discrete items on lower pretax income.
Total assets increased to $16.39 billion from $15.56 billion at year-end 2025, driven by a $1.07 billion rise in cash and cash equivalents to $5.31 billion. Working capital remained steady at $5.1 billion. Investments declined slightly to $3.94 billion. Goodwill and intangibles decreased to $2.09 billion after the $93 million impairment.
Liabilities increased to $12.31 billion from $11.50 billion, primarily due to higher amounts due government agencies ($1.69B vs $1.33B) and deferred revenue ($401M vs $66M). Long-term debt was virtually unchanged at $3.77 billion. Stockholders' equity edged up to $4.08 billion from $4.07 billion, with retained earnings of $3.62 billion.
The parent company held $213 million in cash and investments, and regulated subsidiaries maintained statutory capital above minimum requirements. As of March 31, 2026, the company had $1.25 billion undrawn on its credit facility. The board renewed a $1 billion buyback authorization through December 2026, with $500 million remaining as of April 17, 2026.
Operating cash flow was exceptionally strong at $1.08 billion, compared to $190 million in Q1 2025, benefiting from timing of government receivables and payables, including a $359 million increase in amounts due government agencies and $335 million in deferred revenue. Free cash flow after capex ($27 million) was $1.06 billion. The company did not repurchase any stock in Q1 2026, but used $14 million for employee tax withholding. Investing activities generated net $11 million due to higher proceeds from investment sales.
Management highlighted several strategic shifts: (1) focus on dual-eligible Medicare members with the MMP transition completed and planned exit of MAPD by 2027; (2) Marketplace product and pricing strategy to restore margins, with membership expected to fall to ~250,000; (3) Medicaid enrollment expected to decrease to 4.5 million by year-end due to general market contraction and redeterminations; (4) the One Big Beautiful Bill Act (OBBBA) expected to reduce Medicaid expansion enrollment by 15-20% by 2029, with gradual acuity shifts.
New contract wins in multiple states (Idaho, Michigan, Massachusetts, Ohio, Wisconsin, Nevada, Illinois) are expected to support future growth. The company also noted the S&P downgrade of senior notes to BB- in April 2026, which could increase borrowing costs.
Total medical care costs were $9.27 billion, with favorable prior-year development of $253 million (primarily in Medicaid and Medicare) due to lower utilization than estimated. The impairment of $93 million consisted of contract rights ($62M), provider networks ($4M), and trade names ($27M). Depreciation and amortization decreased to $39 million from $48 million as some intangibles became fully amortized. Interest expense rose to $54 million from $43 million due to the November 2025 note issuance. The company recognized a $93 million impairment charge in Q1 2026 for the planned exit of MAPD, which drove a significant portion of the earnings decline. The effective tax rate spike to 52.8% was attributed to nondeductible expenses and unfavorable discrete items relative to lower pretax income.